Adjuvants play an important role in enhancing vaccine‐induced immune protection.
Adequate cellular uptake, robust lysosomal escape, and subsequent antigen cross …

The inefficient treatment using protein-based nanovaccines is largely attributed to their
inadequate immunogenicity. Herein, we developed a novel fluoropolymer (PF) via ring …

Cancer vaccines have shown promise as effective means of antitumor immunotherapy by
inducing tumor antigen‐specific T cell immunity. In this study, a novel peptide‐based tumor …

Dendritic cells (DCs) are increasingly used in cancer vaccines due to their ability to regulate
T-cell immunity. Major limitations associated with the present DC adoptive transfer …

Background Cancer vaccines are a promising strategy for cancer immunotherapy. Cancer
vaccines elicits a specific cytotoxic immune response to tumor antigens. However, the …

Although powerful adjuvants hold promise of vaccines for cancer immunotherapy,
cumbersome preparation processes, elusive mechanisms and failure to induce T cell …

Peptide vaccine targeting tumor-specific antigens is a promising cancer treatment regimen.
However, peptide vaccines are commonly low-immunogenic, leading to suboptimal …

Tumor vaccines to induce robust immunity for cancer treatment have attracted tremendous
interests in cancer immunotherapy. In this work, a type of cancer vaccine is prepared by …

Weak T cell responses and immune checkpoints within tumors could be two key factors for
limiting antitumor efficacy in the field of cancer immunotherapy. Thus, the combined strategy …

A self-adjuvanting anti-tumor nanoliposomal vaccine based on fluorine-substituted MUC1
glycopeptide - Chemical Communications (RSC Publishing) DOI:10.1039/D2CC02143A …